Whether you're in early-stage development or scaling up for commercial production, eXmoor Pharma provides the expertise and flexibility you need. Partner with us to move your therapy forward with confidence.
eXmoor Pharma and KU Leuven announce strategic partnership to accelerate cell and gene therapy innovation through new venture
May 13, 2025
eXmoor Pharma Strengthens Board with Appointment of Dr James Miskin as Non-Executive Director
Apr 1, 2025
eXmoor and Virica receive funding to improve AAV gene therapy manufacturing
Oct 17, 2024
Quell Therapeutics Expands Manufacturing Capabilities for CAR-Treg Cell Therapy Pipeline Through Partnership
Sep 24, 2024
eXmoor Pharma’s GMP cell and gene therapy manufacturing facility receives license from MHRA
Aug 20, 2024
eXmoor appoints Matthew Paterson as first Chief Commercial Officer
Nov 16, 2023
eXmoor Pharma completes $35 million Series A to expand cell and gene therapy manufacturing capabilities
May 30, 2023
eXmoor Pharma and vaccine developer Imophoron sign process development partnership
Feb 22, 2023
eXmoor to present at OBN BioTuesday: ‘A Spotlight on the Latest Research and Innovation In Cell & Gene Therapy’
Feb 21, 2023
1
2